US keeps India out of Priority Foreign Country list of 'worst IP offenders'

US Trade Representative’s Special 301 Report keeps up pressure on India to fall in line with US’ interests

Novartis loses patent appeal in landmark suit

Supreme Court upholds amended law that bars patents for insignificant improvements to an existing drug—in this case anti-cancer drug …

SC rejects Bayer's appeal against compulsory licence for Nexavar

Indian pharma company, NATCO, can continue manufacturing generic version of liver and kidney cancer drug

Activists demand compulsory licence for another life-saving cancer drug

Appellate board's order upholding Natco's CL for sorafenib tosylate may pave way for manufacture of generic version of other patented drugs

Indian company gets licence to manufacture and sell patented cancer drug

This is the first-ever compulsory licence given to a generic drug company

The NATCO CL fallout

The compulsory licence granted to Natco may not be a trendsetter but it will shake up the pharmaceuticals market

A patent triumph of public interest

New flexibilities make public interest safeguards integral to drug patent rights

The natco-pfizer test

Natco’s demand for a voluntary licence from Pfizer will establish how well the compulsory licence process works in India

Drug affordability test

Natco’s bid for a compulsory licence to manufacture a Bayer anti-cancer drug is a test of the law’s ‘reasonable price’ …

Testing the CL route

Roche’s Herceptin will be a test case for government and generics industry as India readies to issue compulsory licences for life-saving drugs